The Pharmaceutical Journal
Vol 272 No 7281 p6
3/10 January 2004

This article
Reprint
Photocopy

News summary

Pravastatin for diabetes with CHD

Pravastatin prevents cardiovascular events in patients with coronary heart disease and diabetes. A sub-group analysis of the LIPID trial showed that pravastatin 40mg daily reduced the risk of cardiovascular events by 21 per cent (P<0.008) in patients with diabetes (Diabetes Care 2003:26:2713).